MNPR | tickerfilter.com

Fundamental analysis

18%

Profitability 18%

Dept financing 1%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.07%

1 Month

1.75%

3 Months

-25.76%

6 Months

35.36%

1 Year

107.76%

2 Year

6,270.12%

Key data

Stock price

$58.07

P/E Ratio

0.00

DAY RANGE

$53.94 - $58.40

EPS

-$1.33

52 WEEK RANGE

$26.06 - $105.00

52 WEEK CHANGE

$98.33

MARKET CAP

503.901 M

YIELD

N/A

SHARES OUTSTANDING

6.683 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.03

PUBLIC FLOAT

AVERAGE 10 VOLUME

$144,646

AVERAGE 30 VOLUME

$200,385

Company detail

CEO: Chandler D. Robinson
Region: US
Website: monopartx.com
Employees: 10
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

MNPR - Monopar Therapeutics